Search Within

Gabriella D'Andrea-Carlino

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (27)
Groups
  1. Breast Medicine Service (55)
  2. Department of Medicine (55)
  3. Epidemiology and Biostatistics (55)
  4. Solid Tumor Oncology Division (55)
  5. Survivorship Research (55)
  6. Biostatistics Service (48)

More Groups

People
  1. Clifford Hudis (48)
  2. Larry Norton (33)
  3. Diana Lake (32)
  4. Monica Fornier (30)
  5. Sujata Patil (27)
  6. Shanu Modi (25)

More People

Years
  1. 2023 (1)
  2. 2020 (1)
  3. 2018 (2)
  4. 2017 (2)
  5. 2016 (2)
  6. 2015 (4)

More Years

Publications
  1. Journal of Clinical Oncology (15)
  2. Cancer Research (10)
  3. Clinical Cancer Research (8)
  4. Breast Cancer Research and Treatment (7)
  5. Clinical Breast Cancer (6)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Association for Cancer Research (18)
  2. American Society of Clinical Oncology (15)
  3. Springer (8)
  4. Elsevier Inc. (7)
  5. Oxford University Press (3)
  6. Wiley Blackwell (2)

More Publishers

Results (55)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: A randomized trial
    Journal Article

    Scott, J. M.; Lee, J.; Herndon, J. E.; Michalski, M. G.; Lee, C. P.; O'Brien, K. A.; Sasso, J. P.; Yu, A. F.; Rowed, K. A.; Bromberg, J. F.; more...
    European Heart Journal (2023)

    Fulltext@MSK | Save
  • Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer
    Meeting Abstract

    Gucalp, A.; Boyle, L. A.; Alano, T.; Arumov, A.; Gounder, M. M.; Patil, S.; Feigin, K.; Edelweiss, M.; D'Andrea, G.; Bromberg, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Co-targeting ER and FGFR in patients with ER+/HER2- FGFR amplified (amp) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Syed, U.; Wong, S.; D'Andrea, G.; Lake, D.; Goldfarb, S.; Gajria, D.; Ligresti, L.; Rogado, A.; Reis-Filho, J.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel and dasatinib in metastatic breast cancer
    Journal Article

    Morris, P. G.; Rota, S.; Cadoo, K.; Zamora, S.; Patil, S.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; more...
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save
  • Oncologist use and perception of large panel next-generation tumor sequencing
    Journal Article

    Schram, A. M.; Reales, D.; Galle, J.; Cambria, R.; Durany, R.; Feldman, D.; Sherman, E.; Rosenberg, J.; D'Andrea, G.; Baxi, S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Wang, R.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; more...
    Breast Cancer Research (2017)

    Fulltext@MSK | Save
  • A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; Haque, S.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer
    Journal Article

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S. M.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G. M.; Drullinsky, P. R.; Gajria, D.; Goldfarb, S. B.; Comen, E. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save